Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a corporation committed to the production and delivery of medications that make a substantial difference to people afflicted by neurological disorders, announced the addition to its Board of Directors of Spyros Papapetropoulos, MD, PhD. With an emphasis on neurology and previously held R&D and clinical leadership positions at Acadia, Cavion, Teva, Pfizer, Allergan, and Biogen, Spyros offers more than 20 years of academic and business experience. Additionally, Adamas confirmed the departure from the Adamas board of Ivan Lieberburg, MD, PhD.
I’d like to genuinely thank Ivan for his devoted contribution to Adamas. Through numerous successful NDA submissions and Company’s transformation into a successful corporate entity, he played a critical role. We wish him well,’ Adamas Chairman David L. Mahoney said. At this next level of development, we are delighted that Spyros will join us. He would be an excellent addition to our board as a professional research and development leader.
In addition to his track record of introducing meaningful treatments to the market, Spyros’ vast knowledge in neurodegenerative diseases and movement disorders best suited him to bring an important insight to the board,said Neil F. McFarlane, CEO.
At this important moment in the journey towards becoming a leading neurology organization, I am pleased to join Adamas,” said Spyros Papapetropoulos. “I look forward very much to being part of the development and continued success of the company.”
Spyros has led several pharmaceutical research projects during his career, culminating in active regulatory filings and product releases. Spyros has been qualified in London, UK, as a board-certified neurologist and has published more than 160 peer-reviewed publications. Spyros has previously worked on numerous U.S. government and non-profit commissions on progress in healthcare and biomedical research.
